Interview with Dr Orest Lastow November 2018 (only in Swedish)
Skånebolaget Iconovo utvecklar inhalatorer med tillhörande läkemedelsberedning som främst används för att behandla Astma och KOL men Iconovo besitter…
Iconovo at Investor Meeting in Copenhagen
Biotech Invites to Quarterly Conference - This time to Q4.
Tuesday, 27 November 2018 in Copenhagen. Come and meet five exciting listed companies in Biotek…
Iconovo develops new formulations to strengthen the product portfolio (only in Swedish)
Breddat erbjudande med egen utveckling.
Iconovo AB (publ) utökar erbjudandet med egenutvecklade läkemedelsformuleringar för bolagets inhalatorer. Ett…
Iconovo at CPhI in Madrid
Iconovo attended CPhI in Madrid last week which marked the start of our new collaboration with Stevanato Group and ICOcap. Truly an exiting moment and…
ICONOVO SIGNS AGREEMENT FOR DEVELOPMENT OF VACCINE AGAINST TUBERCULOSIS
Iconovo signs an agreement with McMaster University for development of vaccine against tuberculosis
The innovative Swedish medical technology company Iconovo…
Interview with Dr Orest Lastow September 2018 (only in Swedish)
Skånebolaget Iconovo utvecklar inhalatorer med tillhörande läkemedelsberedning som främst används för att behandla Astma och KOL men Iconovo besitter…
MIKAEL EKSTRÖM NEW VP DEVELOPMENT AT ICONOVO
Dr. Mikael Ekström has joined Iconovo as Vice President Development
Mikael has nearly 30 years of experience in inhalation products and has recently come…
Market analys of Iconovo by Erik Penser Bank (only in Swedish)
En välsignelse från Italien
Under kvartalet fakturerade bolaget SEKm 5,5 (7,7), vilket var under vår förväntan om SEKm 8. Avvikelsen ligger i att…
Iconovo signs an agreement with Stevanato Group regarding the manufacture, sale and distribution of ICOcap
The inhalation developer Iconovo AB (publ) announced today that the company has signed an agreement with the multinational Stevanato Group, headquartered…
Dr Orest Lastow is lecturing at Dry Powder Inhalers Annual Conference London 20-21 June 2018
The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great…
